{"name":"Albireo","slug":"albireo","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"A3309","genericName":"A3309","slug":"a3309","indication":"Cholestasis-related pruritus in progressive familial intrahepatic cholestasis (PFIC)","status":"phase_2"},{"name":"A4250 (odevixibat)","genericName":"A4250 (odevixibat)","slug":"a4250-odevixibat","indication":"Progressive familial intrahepatic cholestasis type 1 (PFIC1)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"A3384","genericName":"A3384","slug":"a3384","indication":"Other","status":"phase_2"},{"name":"Questran","genericName":"Questran","slug":"questran","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"A3309","genericName":"A3309","slug":"a3309","phase":"phase_2","mechanism":"A3309 is a bile acid sequestrant that binds bile acids in the intestine to increase their fecal excretion and modulate metabolic pathways.","indications":["Cholestasis-related pruritus in progressive familial intrahepatic cholestasis (PFIC)","Bile acid diarrhea"],"catalyst":""},{"name":"A3384","genericName":"A3384","slug":"a3384","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A4250 (odevixibat)","genericName":"A4250 (odevixibat)","slug":"a4250-odevixibat","phase":"phase_3","mechanism":"Odevixibat inhibits the ileal bile acid transporter (IBAT) to reduce bile acid reabsorption and increase fecal excretion, thereby lowering serum bile acids.","indications":["Progressive familial intrahepatic cholestasis type 1 (PFIC1)","Bile acid diarrhea"],"catalyst":""},{"name":"Questran","genericName":"Questran","slug":"questran","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOVloyTXhjZ2dMcFhCaUdlclM1eGlnUkRSRTN0eG9BZUo0WUpFVDhRWElKSV9iQmRiZUxhS3pBSUZqbUZRZkN3bHNHZDFTSVBMdzZ3OG1uNnVobzJaZlBRQkhmelFhaHBOUFJYVlRXQjFNdFh5SzF2UlRjcHIxZnlGX3pEQTBsUkdoTi1uTHF4endoWnJyTEl4cjBMMG9zeFBHVzhiUG1PSl9JYWN5SzdlSFREaG5KM1NFWVloSS13?oc=5","date":"2025-12-01","type":"patent","source":"Ipsen","summary":"Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 - Ipsen","headline":"Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxNYmFSci16bENER2YwbTRkQXlhbGFhVEZVNmRXdW51R2tDLWpUQVhxSFMtcnZiY2hvSUw1dWc0RUNVWFpXOEtvakxjLUtVNTdOVG9iOFJRbTF0VnVNNjRLUHBEZXk1a0xOVzA3YnJ0S1lGVjh2VUN1dEo1WWh3SmU4MkxlWE9kTm5XMWxxMFVMakdQc3BQZ2VBVFJHekRvN0I1XzhGazA5QjhRUQ?oc=5","date":"2023-07-10","type":"pipeline","source":"Timmerman Report","summary":"Lessons Learned from the Intense Back-and-Forth Over a $1B Acquisition - Timmerman Report","headline":"Lessons Learned from the Intense Back-and-Forth Over a $1B Acquisition","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxOUDN5T2Y3WF9ZeVFlNjdMVkNzeWJSbVpFUi00SVNGMklnc3VjbnAxYVYyQ01ET0NGYURVRG1JVV9MQ3RRYkJ1QVpQNUE4MlpoMExKV3BCMER3cTZYRGgyRi1RVEY0N3FoaWlEQXZFcDN4a3VZUzRJcGs1Tldsak91S21Qbw?oc=5","date":"2023-03-03","type":"pipeline","source":"Pharmaceutical Technology","summary":"Ipsen concludes purchase of Albireo Pharma - Pharmaceutical Technology","headline":"Ipsen concludes purchase of Albireo Pharma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPaThLRDNLaWxEdDB1ZXVhMUJuZi12dVREX2JDWmVBWHVUY05ZRWJrbTFoZ1hTRGRTU0RvVGtBbWFoeUhxcHdnbERZb2d6VFE4U1pJdDIyT1pxdVlWeXB3OS1lc19iUUtZNDJvM0dlYU96VkFjc2c0aExhZlZWSnUxWmgweXo1blBqaE1OaVB0SG1ueWtjSmIxa2ItcFhkY3BHajNJUlUybUlJb0diRXd3Z2ZidkEwbk8wSEtCRW9wb3p0cGM?oc=5","date":"2023-03-02","type":"pipeline","source":"Ipsen","summary":"Acquisition of Albireo has been completed | Ipsen Global - Ipsen","headline":"Acquisition of Albireo has been completed | Ipsen Global","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxOeEJTYm5LYndvcGhGNHc3bWVnZEZ1bURySVNvYWQ5REZiWFFmQ1RHN1FVNlZxeFN4eHhlME1jUFdZRVFOMEZiMGoxWGdBT21ETG5RajlNTEZmUHFucklmUTRPZEJUeko4SFk3X3NrcG44emxobjVUZUstMC1vb3FqeDdWQnNORkU2QURzd05tZ21OSWdPOWctZUVQZlZTR29P?oc=5","date":"2023-01-10","type":"deal","source":"Seeking Alpha","summary":"Albireo Pharma Stock: Elucidating The Ipsen Buyout (Rating Upgrade) (NASDAQ:ALBO) - Seeking Alpha","headline":"Albireo Pharma Stock: Elucidating The Ipsen Buyout (Rating Upgrade) (NASDAQ:ALBO)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOck1sdnhTUWotaThIWkFFYVM1UmxRblF6MDhDcm5FQkZfbHlYYUNvbnVsdjY1bnpvbmJNMzNDV2VGVUd3dXprV2FCTXNwQ2M2S0Zia1REOU5sY1dHbUZtNFYwdTU3V1BrOGcyTVM5aGY3WUVFd1BESVdzcVRhMVB6dTJGZmFtTWNzNndfU3h1ZmtkUFR3TmhpeFBJczM?oc=5","date":"2023-01-09","type":"pipeline","source":"Fierce Pharma","summary":"JPM23: Ipsen scoops up liver disease specialist Albireo for $952M - Fierce Pharma","headline":"JPM23: Ipsen scoops up liver disease specialist Albireo for $952M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPNENYdVgxZUVhUElUY3czX3VPRGptWEJMSXZ0T0dXSWhiaUhBNWV2dDZrWmRGZndqSU4yN3JqTWtwTjEyWU9VYzZFczhSTC1fMXhzRjVaWkc3TmpCckQySmcyVF9nRVlCX1A5U3c2SktzNDQzdlhNNWNSNFVIa1Q1YzBLdnF3R1ZI?oc=5","date":"2023-01-09","type":"deal","source":"finance.yahoo.com","summary":"France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline - finance.yahoo.com","headline":"France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNVzJRTmptUUNHZHhEb3N1dzg5QlpYNXBCbld6Z3AtQlZFLVN3ckhaTjdQZ1BtQ2pBbk5RRDZmMVNUdldoMjM5LUpKSGxUNFF3Ml9DLWtfbnl5RzN2ejhtX3pNT3lMRDVST3c5SEVKWkhhSzd3ejY1S2hneXplNU9hX19nbjR3bUtHUDZLSzJ6OGFSSDBudEl5ejVublRIaFR1RmZQRTBrZXZ2QmZRSFRQdVVmcWFzbFBpRG53?oc=5","date":"2023-01-09","type":"pipeline","source":"orrick.com","summary":"Orrick Advises Ipsen on Acquisition of Liver Disease Treatment Innovator Albireo - orrick.com","headline":"Orrick Advises Ipsen on Acquisition of Liver Disease Treatment Innovator Albireo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxPcXpmanJDMlN4MG9LNmpuUVR4Z2lMNEdLd1A4SXRGY3ktQ25kRmQ0TVctTFdwa3NUTlBTZ3l6Z0FiMUlCMzVNRW5Cd2lqbi1IQWdrOC1OQmNhel9YUmM0aVVxY0VoRDJJQmIyOXJpNlB0Y3NCeFczMmlrLVJfRkNLRU9waE1tUVBGUDgwbVZabmwzZDl6djVhNDFlWlpjbWJibURuSnlldFZ0N2RQdzhEdHFBcVRiSXFTeDFxUlIxQTczd0Z1VlJOTGZGT0dRc3Fzcmw3TVNFMmlaLUNH?oc=5","date":"2022-09-22","type":"pipeline","source":"globenewswire.com","summary":"Albireo Announces $115 Million Royalty Monetization Agreement with Sagard - globenewswire.com","headline":"Albireo Announces $115 Million Royalty Monetization Agreement with Sagard","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNYUZ2aWcwS1d4UE40azNJbnNxLUU3ajI5RmpNQVRjVVZUYWt3ajNGdDBwM2RBRHNHdk9xbXBqdG1aNXdlYzhiZFpWcnEwTXc5SGZNaWxCaTNIQVRoNXN1bEJzcjNIcXJNU1FLbWI4RWV1X1JOX2RlMzh0RG5iLXc1bEgzWFNSUGZVenptRXVmN3VWRWFwRzFQRnJLdTM0NnpEb3JDZHVkbE5mRjlBcWxSdWkzc21nMlBFUEhQeGFUSjJmb2dJNnJVa2ZiVkdYZlZIYTh5ZnJlbU5MVjZIUjI4STVtVEtWem81ckZaVHpHWXdON3BrY1I5SjRKSEZVa2NLVURHYmwtQWU5QVJvQm8ySU1OUWJDMU1KNUFjcTEyV25CdnAwMDJMM25xREJwZw?oc=5","date":"2022-08-16","type":"deal","source":"PR Newswire","summary":"Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Odevixibat in Canada and Israel - PR Newswire","headline":"Medison Pharma Announces the Expansion of its Partnership with Albireo to a Multi-Regional Agreement to Commercialize Od","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxPWjhxTThNV2M4WFpqVWdGWWhvV2dabm9aUU50dFFsYVFreFF4eVREWVNsbkw4YTlydkhRMGtfSnliRUY3Uk45OXZBRGxRRnFGQWt4Y05pTEgzeGRMenNLV3pneDdyMHpNcW5YR0dXYXhiV2wySFdCcG9iLXFhdE9IaDFOeFFrWG5KMnpFYjJHMWg4aDFlcHdhVHc5dWxCM3VrTlZPdjF4aE5RMktla3hqRkpqNTBTR09SNjZOYVY4WmdKa3FYMUt4Y2NOa1g?oc=5","date":"2022-07-01","type":"pipeline","source":"Life Science Leader","summary":"Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper - Life Science Leader","headline":"Transitioning To Orphan Drug Commercialization: A Q&A With Albireo Pharma's CEO Ron Cooper","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxONHJlOFo2OTRHZHlMNmpndXkyVDlOU3BPNHVBZkQ0RXNNLW54aFFOblF1Z3QwWG4td0Jac01yWldpQzlXRnlqZEZ3bThtTnhza2xweUgzX05Zc1RlMmRIUGlQamppNURYQ2Nmb0tCNlVfSDZqeGJfWDhGWkVTSi1oX0piUVhRbTF1?oc=5","date":"2019-08-01","type":"pipeline","source":"massbio.org","summary":"Member Spotlight: Q&A with Albireo Pharma - massbio.org","headline":"Member Spotlight: Q&A with Albireo Pharma","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_2":2,"phase_3":1,"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}